Detailed Information

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis

Cited 2 time in Web of Science Cited 1 time in Scopus

Park, Ha-Ram; Kim, Seong-Eun; Keam, Bhumsuk; Chung, Hyewon; Seok, Seung Hyeok; Kim, Soyeon; Kim, Miso; Kim, Tae Min; Doh, JunsangKim, Dong-Wan; Heo, Dae Seog

Issue Date
Nature Publishing Group
Scientific Reports, Vol.12 No.1, p. 12546
Immune checkpoint inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) are mainstream treatments for renal cell carcinoma (RCC). Both T cells and macrophages infiltrate the tumor microenvironment of RCC. CD47, an immune checkpoint of macrophages, transmits the "don't eat me" signal to macrophages. We propose a novel therapeutic strategy that activates the antitumor effect of macrophages. We found that CD47 was expressed in patients with RCC, and high CD47 expression was indicative of worse overall survival in datasets from The Cancer Genome Atlas. We observed that CD47-blocking antibodies enhanced the antitumor effect of macrophages against human RCC cell lines. Trogocytosis, rather than phagocytosis, occurred and was promoted by increased cell-to-cell contact between macrophages and RCC cells. Trogocytosis induced by CD47 blockade occurred in the presence of CD11b integrin signaling in macrophages and was augmented when RCC cells were exposed to VEGFR TKIs, except for sunitinib. In conclusion, this study presents evidence that anti-CD47 blocking antibodies improve the antitumor effect of macrophages in RCC. In combination with VEGFR TKIs, CD47 blockade is a potential therapeutic strategy for patients with RCC.
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Engineering
  • Department of Materials Science & Engineering
Research Area Ex Vivo Models, Lymphocyte Biology, Smart Biomaterials


Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.